Outcome of Board Meeting

Ref. No.: 2026-27/026 July 23, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, 5th Floor Phiroze Jeejeebhoy Towers Bandra-Kurla Complex Dalal Street Bandra (E), Mumbai 400 051 Mumbai 400 001. Symbol: COROMANDEL Scrip Code: 506395 Dear Sirs/Madam, Sub : Outcome of the Board Meeting - Intimation about the Unaudited Financial Results for the quarter ended June 30, 2026 and disclosures under Regulation 30 Further to our letter dated July 17, 2026, we wish to inform that the Board of Directors at its meeting held today i.e., July 23, 2026, have approved the following: 1. Unaudited Financial Results for the quarter ended June 30, 2026 approved the un-audited financial results (standalone & consolidated) of the Company for the quarter ended June 30, 2026 as recommended by the Audit Committee at their respective meeting(s) held today (July 23, 2026). The unaudited financial results (standalone & consolidated) of the Company for the quarter ended June 30, 2026 are enclosed along with the Limited Review Report on both standalone & consolidated results issued by M/s. S R Batliboi & Associates LLP, Chartered Accountants, Statutory Auditors. (Regulation 33). The unaudited financial results (standalone & consolidated) will be uploaded on the website of the company at www.coromandel.biz and stock exchanges at www.bseindia.com and www.nseindia.com (Regulation 46). 2. Disclosure under Regulation 30 of the Listing Regulations i. Approved conversion of loan value amounting to about Rs. 108 Crores to equity shares of face value of Rs. 10/- each of Coromandel Chemicals Limited, a wholly owned subsidiary of the Company, at an issue price of Rs. 39.95/- per equity share (including premium). ii. Approved the restructuring of loans amounting to USD 9.70 Million, that has been given to Baobab Mining and Chemicals Corporation S A (BMCC), a step-down subsidiary of the Company, held through Coromandel Chemicals Limited (CCL) into equity or preference shares with optionality or such other instruments, as may be mutually agreed. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, for the above is subject to certain further actions and hence will be provided at the appropriate time. The Meeting of the Board of Directors commenced at 11:00 a.m. and concluded at 02: 00 p.m. We request you to acknowledge and take it on your record. Thanking you, Yours sincerely, For Coromandel International Limited B Shanmugasundaram Company Secretary & Compliance officer Enclosure: As above. COROMANDEL INTERNATIONAL LIMITED (CIN: L24120TG1961PLC000892) Registered Office: 'Coromandel House', 1-2-10, Sardar Patel Road, Secunderabad -500 003. Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30 June 2026 (f in Cr-ore•) Standalone results ConsoUdated results Unaudited Refer Note 5 Unaudited Audited Unaudited Refer Note S Unaudited Audited Particulars Quortc, ended Year ended Q~ar1cr ended Year cnd~d 30 June 31March 30 June 31March 30June 31March 30June 31March 2026 2026 2025 2026 2026 2026 2025 2026 1 Income (a) Revenue from operations 7,743.55 5,660.90 7,ll0l.32 30,530.89 8,164.77 6,003.66 7,042.30 31,479,54 (b) Other income 48.76 87.35 81.60 350.62 49.81 64,50 83.74 347,91 Total income 7,792.31 5,748.25 7,082.92 30,881.51 8,214.58 6,068.16 7,126.04 31,827.45 2 Expenses (a) Cost of raw materials and packing materials consumed 4,371.80 4,059.82 3,604.26 16,930.53 4,615.19 4,151.78 3,566.90 17,230,76 (b) Purchases of traded goods 2,665.60 K23.76 2,347.54 7,846.13 2,667.18 824.32 2,347.14 7,853.87 (c) Changes in inventories of fu1islu~d goods, work-in-progress and traded goods (958.69) (700.15) (638.45) (1,440.92) (1,100.26) (657.16) (675.22) (1,415.59) (d) Employee benefits expense 244.14 221.77 217.32 906.86 300.83 272.71 225.44 1,048 85 (e) Finance costs 75.94 74.92 65.28 287.39 89.02 89.32 67.96 34259 (f) Depreciation and amortisation expense 88.03 84.46 69.75 296,77 202.76 164.73 120.58 533.62 (g) l're1ght and distribution expense 400.62 327.12 352.18 1,502.04 431.34 352,52 381.09 1,577.03 (h) Other expenses 399.53 469.97 380 50 1,684.68 494,84 571.71 414.83 1,968.56 Total expenses 7,286.97 5,361.67 6,398.38 28,013.48 7,700.90 5,769.93 6,448.72 29,139.69 3 Profit before share ofprofit/(loss) of joint venture and associates and exceptional items (1-2) 505.34 386.58 684.54 2,868.03 513.68 298.23 677.32 2,687.76 4 Share ofloss of joint vcnrurc and associates (net) . (0.02) (0,04) (0.06) 5 Profit before exceptional items and tax (3+4) 505.34 386.58 684.54 2,868.03 513.68 298.21 677.28 2,687.70 6 l -'.xcL1)tional items (refer note 2) (125.15) (125.15) (70.56) (70.56) 7 Profit before tax (5+6) 505.34 261.43 684.54 2,742.88 513.68 227.65 677.28 2,617.14 8 Tax expense (a) Current tax 109.67 91.71 177.31 736.90 110.53 93.09 177.40 738.94 (b) Deferred tax 18.71 15.41 (1.00) (2,60) 21.59 19.92 (1.71) (19.94) Total tax expense 128.38 107.12 176.31 734.30 132.12 113.01 175.69 719.00 9 Net profit after tax (7-8) 376.96 154.31 508.23 2,008.58 381.56 114.64 501.59 1,898.14 Attributable to (a) Owners of the Compan}' 380.82 139.93 505.01 1,956.15 (b) ~on-controlling inte1ests 0.74 (25,29) (3.42) (58.01) 376.96 154.31 508.23 2,008.58 381.56 114.64 501.59 1,898.14 10 Other comprehensive income /te,m /h{I/ wi/1110/ be rer/{l.r.rified subsu1uml/y lo pref,! or IOJs N"et fair value g.1.in/Qoss) on investments at I·VTOCI 7.-16 . 7.46 . 25.55 . 25.55 Remeasurcme11t 1-,rain/0oss) on defined benefit plans (10.07) (9.53) (0.54) (9.63) (9.45) Income tax on above 1.-17 1.33 0.14 (1.27) (1.32) /tam thal J11ill be redass!fied s11bsu111e11l!J lo projil or IOJs Effective portion of brai.11/ 0oss) on designated portion of hedging instruments in a cash flow hedge (17.56) 17.56 0.20 17.76 (17.56) 17.56 0.20 17.76 I~ xchange differences on translation of foreign operations 1,72 18.17 (1.13) 45.90 Income tax on above 4.42 (4.42) (0.05) (4.47) 4.42 (4.42) (0.05) (4.47) Total other comprehensive income/(loss), net of tax (13.14) 12.00 0.15 12.55 (11.82) 45.96 (0.98) 73.97 1\ttributablc to (a) Owners of the.: Company (11.68) 44.42 (0.65) 65.05 (b) :\;on-controlling interests (0.14) 1.54 (0.33) 8.92 11 Total comprehensive income (9+ 10) 363.82 166.31 508.38 2,021.13 369.74 160.60 500.61 1,972.11 Attributable to -- (a) Owners of the Company ,~tern~~o 369.14 184.35 504.36 2,021.20 (b) Non-controlling interests 0.60 (23.75) (3.75) (49.09) 12 Paid-up equity share capital (l"ace value t I per equity share) b - -, 29.50 29.50 29.48 29.50 29.50 29.50 29.48 29.50 13 Othcreyuity ,~ c1':ai El 12,444.78 12,528.39 14 Earnings per share (oH I each) ("_ ~l{!}),<.91 $-,S,o~ mli.se<l) i;} 'f • Basic (~ "'° _ ~ ,~./2 12.80 5.24 17.26 68.19 12,93 4.75 17.15 66.41 -Diluted (t) 11 -~9 ~,,, ~o.,ri 12.79 5.24 17.23 68.09 12,92 4.75 17.12 66.31 a-: :.,~ AC·: $''~ ANTS J:;. I ~ -"Jt 'r'_..6/ <Jl_ bJ ,_.DERf'-£>~ Notes: The above unaudited standalone and consolidated financial results of Coromandcl International Limited ("the Company"), which have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act'') read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("Sl•:Jll") were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meetings held on 23 July 2026. The Statutory Auditors have carried out a limited review and issued unmodified reports thereon. 2 l•:xceptional items for the quarter and year ended 31 March 2026 represent estimated provision towards impairment of investment/goodwill relating to Company's Drones subsidiary business. This is primarily on account of delay in execution of certain [Showing first 8,000 characters — download PDF for full document]